Who Pays for Australia's Medicines? The Economics Behind the PBS
- Written by The Times
Australians rarely think about the true cost of prescription medicines. A patient might pay $25 for a medicine at the local pharmacy, or $7.70 if they hold a concession card. Yet the medicine itself may cost hundreds—or even thousands—of dollars.
The difference is funded by Australian taxpayers through the Pharmaceutical Benefits Scheme (PBS), one of the largest healthcare purchasing programs in the nation.
The PBS is more than a health policy. It is a sophisticated economic partnership between government, pharmaceutical companies, pharmacists and patients that seeks to balance innovation with affordability.
Why Governments Subsidise Medicines
At first glance, subsidising medicines appears expensive.
However, governments view medicine as an investment rather than simply an expense.
Effective medicines can prevent heart attacks, reduce hospital admissions, control chronic illnesses, improve workforce participation and allow Australians to live independently for longer. Treating disease early is often significantly less expensive than treating complications later.
In economic terms, every prescription has the potential to avoid much larger healthcare costs elsewhere in the system.
A Multi-Billion Dollar Commitment
Each year the Commonwealth spends many billions of dollars subsidising PBS medicines, making it one of the largest areas of health expenditure outside hospitals and Medicare. The PBS covers hundreds of millions of prescriptions annually, with government paying the difference between the medicine's negotiated price and the patient's capped contribution.
That scale gives Australia considerable purchasing power.
Unlike individual consumers, the Australian Government negotiates with pharmaceutical manufacturers on behalf of almost the entire population.
Why Drug Companies Accept Lower Prices
A natural question follows.
If Australia negotiates lower prices, why do pharmaceutical companies agree?
The answer is certainty.
Without PBS listing, many Australians could not afford newer medicines, dramatically reducing sales volumes.
A successful PBS listing provides manufacturers with access to a stable national market, predictable demand and reliable government payment.
Although the price per prescription is lower than it may be in some overseas markets, the certainty of large-scale sales often makes PBS participation commercially attractive.
The Generic Medicine Advantage
Not all medicines remain under patent forever.
When patents expire, other manufacturers may produce generic versions containing the same active ingredient.
Competition between manufacturers typically reduces prices substantially.
These savings benefit both taxpayers and patients while allowing governments to redirect funding towards newer, more expensive breakthrough therapies.
Generic medicines have become one of the major reasons Australia has been able to expand the PBS while managing overall costs.
The Challenge of New Therapies
Modern medicines are becoming increasingly specialised.
Gene therapies, personalised cancer treatments and biologic medicines can cost tens or even hundreds of thousands of dollars per patient annually before government subsidies.
Each new therapy raises important economic questions.
Should taxpayers fund every new medicine regardless of cost?
How much additional health benefit justifies additional public expenditure?
These questions are considered before medicines are added to the PBS, ensuring that public money is directed towards treatments providing meaningful clinical benefit relative to their cost.
Can Australia Afford It?
Australia's population is ageing.
More people are living with chronic conditions requiring long-term medication, while scientific advances continue producing highly sophisticated—and often expensive—new treatments.
Maintaining the PBS will require ongoing negotiation between governments, pharmaceutical companies and healthcare providers.
The challenge is not whether Australians value affordable medicines—they clearly do—but how to fund them sustainably over coming decades.
More Than a Health Program
The PBS is sometimes viewed simply as a subsidy.
In reality, it also acts as one of Australia's largest procurement systems.
It influences pharmaceutical investment, shapes pharmacy businesses, supports nationwide medicine distribution and gives Australia leverage in global pricing negotiations.
Few government programs combine health policy, economics and commercial negotiation on such a large scale.
The Times Health View
Australians often judge the PBS by what they pay at the pharmacy counter. The real story begins much earlier. Behind every subsidised prescription lies a complex negotiation between science, commerce and government. The success of the PBS is not measured only by lower prices, but by its ability to ensure that innovative medicines remain accessible while keeping the healthcare system financially sustainable for future generations.
